



JPND
research

EU Joint Programme – Neurodegenerative Disease Research

JPND - promoting engagement, commitment and partnerships

Enda Connolly
CEO, Health Research Board
Ireland

An international health and economic emergency

- Between now and 2050, over 680 million new cases of dementia will be diagnosed worldwide ¹
- **That's 680 million people living with dementia in the next 40 years!**
 - more than the population of all of North America (542 million) and nearly as much as all of Europe (738 million)
- ND are the most expensive of all known diseases
 - Global cost of dementia in 2010 is \$604 billion - 1% of global GDP ²
- Current economic crisis is affecting research budgets

JPND Research

Basic

Clinical

Healthcare/Social

PARTNERSHIP

- **JPND Members (27)**
 - **Member States**
 - **Assoc. Countries**
 - **Third Countries**
- **European Commission**
- **Industry**
- **Public and Users**

ACTIONS

- **Common Strategy**
- **Transnational Calls**
- **Collaborative Actions**
- **National Plans**
- **Coordination between plans**
- **Communications & Dissemination**

OUTCOMES

- **New treatments and preventive strategies**
- **Improved health + social care approaches**
- **De-stigmatize ND**
- **Alleviate economic and social burden**

JPND - Sharing the challenge – 27 countries

- “Member State” led Initiative
- EU Member States, Associated Countries and 3rd Countries - Working together through JPND
 - *Croatia, Austria, Israel and Canada over last 12 months*
- Collaborative funding and actions
- In Europe, greatest amount of funds available for ND research is through national budgets
- Encouraging Members to synchronise National ND Plans with JPND EU Research Strategy



National Research Plans in Europe

- Countries at various stages of development
- JPND actions to stimulate National plans
 - Mapping Exercise
 - Templates, case studies and some funding
- Typical approach
 - National steering committees – all stakeholders
 - National Mapping of ND research
 - Strengths and weakness assessment
 - Gaps analysis aligned to EU strategy
 - Funding dedicated or linked to EU co-fund
- Increasingly aligned to JPND Research Strategy



Third Country Collaboration

- Recognition of global challenge
- JPND open to Third Country engagement from the outset
- Canada participate in COEN, JPND Pilot call
 - May 2012 – Canada first full Third Country member
- JPND Policy in place – available at www.jpnd.eu



Third Country Collaboration - Policy

Membership:

- Consensus is the “modus operandi”
- Full Participation in all activities and action
- 2 non voting members with mandate on Management Board
- Capacity to participate and influence all discussions and decisions.
- “Virtual Pot” funding



- Existing Bi-Lateral or Multilateral agreements with JPND members
- Support of two JPND members
- Outline of significant investment in ND research
- Indication of level of anticipated participation
- Nomination from National Authority



Partnering with EU Commission

- Facilitated establishment of joint programming initiative
- Encouraging collaborative approach to research across EU
- Advocating partnership with Member States
- Mutual leverage of funding – Discussions underway
- “Horizon2020” priority
- Support at the highest political levels



Collaboration with Industry

- Substantive participation in development of JPND Research Strategy
 - Now Members of Scientific Advisory Board
 - Discussions with EFPIA-IMI – funding within JPND Research strategy
 - JPND Industry Action Group to develop new public-private-partnerships
- 
- A decorative graphic in the bottom right corner consisting of several overlapping, curved lines in various colors (blue, green, yellow, red, purple) that form a partial arc.

Public and User Engagement

- Patient and Public consultation for development of JPND Research Strategy
- JPND Action Group on Public and User involvement in research
- On-going Stakeholder Engagement process
- JPND Communications and Dissemination



Thank you!



 @JPNDEurope

